Welcome to The Visible Embryo
The Visible Embryo Birth Spiral Navigation
Fetal Timeline--- -Maternal Timeline-----News-----Prescription Drugs in Pregnancy---- Pregnancy Calculator----Female Reproductive System

WHO International Clinical Trials Registry Platform

The World Health Organization (WHO) has a Web site to help researchers, doctors and patients obtain information on clinical trials.

Now you can search all such registers to identify clinical trial research around the world!




Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System


Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.

Content protected under a Creative Commons License.
No dirivative works may be made or used for commercial purposes.


Pregnancy Timeline by SemestersDevelopmental TimelineFertilizationFirst TrimesterSecond TrimesterThird TrimesterFirst Thin Layer of Skin AppearsEnd of Embryonic PeriodEnd of Embryonic PeriodFemale Reproductive SystemBeginning Cerebral HemispheresA Four Chambered HeartFirst Detectable Brain WavesThe Appearance of SomitesBasic Brain Structure in PlaceHeartbeat can be detectedHeartbeat can be detectedFinger and toe prints appearFinger and toe prints appearFetal sexual organs visibleBrown fat surrounds lymphatic systemBone marrow starts making blood cellsBone marrow starts making blood cellsInner Ear Bones HardenSensory brain waves begin to activateSensory brain waves begin to activateFetal liver is producing blood cellsBrain convolutions beginBrain convolutions beginImmune system beginningWhite fat begins to be madeHead may position into pelvisWhite fat begins to be madePeriod of rapid brain growthFull TermHead may position into pelvisImmune system beginningLungs begin to produce surfactant
CLICK ON weeks 0 - 40 and follow along every 2 weeks of fetal development


Folic acid late in pregnancy may increase allergies

Taking additional folic acid in late pregnancy may increase the risk of allergies in children affected by growth restriction during pregnancy...

Allergies are one of the main causes of non-communicable diseases in the world and are estimated to affect 30-40% of the world's population. Susceptibility to allergies after birth is partly determined by the environment an individual is exposed to in early life. Now, research from the University of Adelaide in Australia, suggests that taking folic acid in late pregnancy may also increase the risk for allergies in children affected by growth restriction during their development in utero.

Intrauterine growth restriction (IUGR) is determined by fetal weight. If weight falls below the 10th percentile of normal, measured as gestational age determined by ultrasound, it can also be called small-for gestational age (SGA) or fetal growth restriction. IUGR occurs in an estimated 2.5 to 3 percent of pregnancies. Folic acid is a type of B vitamin widely used to prevent neural tube defects in a fetus, and to aid in development of the fetal central nervous system. The neural tube develops in the first month of pregnancy, and Australian guidelines recommend that women take a daily folic acid supplement at least one month before, and three months after conception.

"Taking a folic acid supplement during the first trimester of pregnancy is important to reduce the risk of neural tube defects. However, continued supplementation with folic acid into the later stage of pregnancy doesn't reduce that risk, with growing evidence this may increase the risk of allergies in offspring," explains Kathy Gatford PhD, of the University of Adelaide Robinson Research Institute in Australia. The research is published in the American Journal of Physiology.
Previous research has also shown that a complication of pregnancy known as intrauterine growth restriction (IUGR) - a form of growth restriction in the womb often resulting in lower birth weight - may in fact have a protective effect against childhood allergies.

In studies of sheep born from normal and growth-restricted pregnancies, Dr Gatford and colleagues measured skin reactions to two common allergens: dust mites and egg whites. "Sheep from growth-restricted pregnancies were less likely to have allergic reactions to egg white protein than those born to normal pregnancies. Importantly, if the sheep with growth restricted pregnancies were fed supplements containing folic acid in late pregnancy, their offspring had similar rates of allergic reactions as control progeny," says Gatford.

Gatford continues: "Our findings suggest that folic acid supplementation partially reduced protection that has previously been seen in pregnancies with restricted growth. While results help us understand the potential allergy risk in humans, more research is needed before any recommendations about the right timing of supplementation should or could be made in humans.

Perinatal exposures are associated with altered risks of childhood allergy. Human studies and our previous work suggest that restricted growth in utero (IUGR) is protective against allergic disease. The mechanisms are not clearly defined, but reduced fetal abundance and altered metabolism of methyl donors are hypothesized as possible underlying mechanisms. Therefore, we examined whether late-gestation maternal dietary methyl donor and cofactor supplementation of the placentally restricted (PR) sheep pregnancy would reverse allergic protection in progeny. Allergic outcomes were compared between progeny from control pregnancies (CON; n = 49), from PR pregnancies without intervention (PR; n = 28), and from PR pregnancies where the dam was fed a methyl donor plus cofactor supplement from day 120 of pregnancy until delivery (PR + Methyl; n = 25). Both PR and PR + Methyl progeny were smaller than CON; supplementation did not alter birth size. PR was protective against cutaneous hypersensitivity responses to ovalbumin (OVA; P < 0.01 in singletons). Cutaneous hypersensitivity responses to OVA in PR + Methyl progeny were intermediate to and not different from the responses of CON and PR sheep. Cutaneous hypersensitivity responses to house dust mites did not differ between treatments. In singleton progeny, upper dermal mast cell density was greater in PR + Methyl than in PR or CON (each P < 0.05). The differences in the cutaneous allergic response were not explained by treatment effects on circulating immune cells or antibodies. Our results suggest that mechanisms underlying in utero programming of allergic susceptibility by IUGR and methyl donor availability may differ and imply that late-gestation methyl donor supplementation may increase allergy risk.

Authors: Amy L. Wooldridge, Robert J. Bischof, Hong Liu, Gary K. Heinemann, Damien S. Hunter, Lynne C. Giles, Rebecca A. Simmons, Yu-Chin Lien, Wenyun Lu, Joshua D. Rabinowitz, Karen L. Kind, Julie A. Owens, Vicki L. Clifton, and Kathryn L. Gatford

This work was supported by project grants (ID nos. 627123 and 1011767) from the National Health and Medical Research Council of Australia. H. Liu was supported by a University of Adelaide Faculty of Health Sciences Postgraduate Scholarship. D. S. Hunter and A. L. Wooldridge were supported by Australian Postgraduate Awards, and A. L. Wooldridge was the recipient of a Healthy Development Adelaide scholarship. The Penn Diabetes Metabolomics Core at Princeton University was funded by National Institute of Diabetes and Digestive and Kidney Diseases Grant P30-DK-19525.

No conflicts of interest, financial or otherwise, are declared by the authors.

Return to top of page

Jan 2, 2018   Fetal Timeline   Maternal Timeline   News   News Archive

Researchers recommend that pregnant women should continue to include folic acid supplements
in their diet. But, patients should be aware of the potentially increased risk of childhood allergies
from continuing folic acid through an entire pregnancy.

Phospholid by Wikipedia